[New drug approval: Nivolumab for adjuvant treatment of patients with PD-L1-positive (≥1%), muscle invasive urothelial carcinoma who are at high risk of recurrence after radical resection]

Bull Cancer. 2022 Oct;109(10):992-993. doi: 10.1016/j.bulcan.2022.05.006. Epub 2022 Aug 19.
[Article in French]
No abstract available

Keywords: Adjuvant treatment; Anti-PD1; Cancer urothélial; Immunotherapy; Immunothérapie; Traitement adjuvant; Urothelial carcinoma.

Publication types

  • Letter

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • B7-H1 Antigen
  • Carcinoma, Transitional Cell* / drug therapy
  • Drug Approval
  • Humans
  • Immunotherapy
  • Muscles / pathology
  • Nivolumab / therapeutic use
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / pathology
  • Urinary Bladder Neoplasms* / surgery

Substances

  • Adjuvants, Immunologic
  • B7-H1 Antigen
  • Nivolumab